Compare EPM & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EPM | RANI |
|---|---|---|
| Founded | 2003 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medicinal Chemicals and Botanical Products |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.3M | 134.6M |
| IPO Year | 1996 | 2021 |
| Metric | EPM | RANI |
|---|---|---|
| Price | $4.08 | $1.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $4.75 | ★ $8.67 |
| AVG Volume (30 Days) | 431.3K | ★ 2.7M |
| Earning Date | 11-11-2025 | 11-06-2025 |
| Dividend Yield | ★ 11.78% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $85,232,000.00 | $1,200,000.00 |
| Revenue This Year | N/A | $414.59 |
| Revenue Next Year | $2.97 | $30.15 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.71 | $0.39 |
| 52 Week High | $5.70 | $3.87 |
| Indicator | EPM | RANI |
|---|---|---|
| Relative Strength Index (RSI) | 45.32 | 40.73 |
| Support Level | $4.02 | $1.52 |
| Resistance Level | $4.27 | $1.67 |
| Average True Range (ATR) | 0.10 | 0.13 |
| MACD | 0.04 | -0.04 |
| Stochastic Oscillator | 62.00 | 3.04 |
Evolution Petroleum Corp is an independent energy company focused on owning and investing in onshore oil and natural gas properties across the United States. Its portfolio includes non-operated interests in various production fields such as CO2 enhanced oil recovery in Louisiana, secondary recovery production in Wyoming, and shale gas reservoirs in Texas and North Dakota. The company generates revenue from the production and sale of oil and natural gas, leveraging specialized technologies to extend reservoir life and enhance recoveries.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.